Dr Dirk Wildemeersch, MD, PhD (1944-2018) completed his medical training at the University of Ghent, Belgium, and graduated in gynecology in 1976, in South Africa.
Dr. Wildemeersch is the developper of several innovative contraceptive systems, including GyneFix, Gyn-CS, ReLARC, Femilis Cu, Femilis LNG and Fibroplant.
For more than 40 years, he was a devoted gynaecologist to his patients and dedicated a substantial part of his time to the clinical development of new IUD concepts and implant systems, originally in collaboration with a group of gynecologists from the University of Ghent, Belgium, under the name IUD-group which later became the International Study Group on Intrauterine Drug Delivery. Under Dr. Wildemeersch’ supervision, a research organization, Contrel Research, was established to manage clinical research and to continue to develop and study innovative drug delivery technologies, aimed at finding improved methods for the prevention and treatment of gynecological disorders, improvements to birth control methods, with higher levels of safety, user acceptability, compliance and quality of life of women. His main topics of research were contraception, including long-acting reversible intrauterine contraception, and intrauterine drug delivery for the treatment of menorrhagia and other gynaecological conditions including postmenopausal treatment.
His work is acknowledged by leading research organizations such as the World Health Organization (Reproductive Health Research) in Geneva and by the Population Council in New York.
Following his untimely passing in 2018, his wife, Rina Wildemeersch, has vowed to continue his mission and research.
For more information visit
www.wildemeersch.com